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Introduction
Perfluoroalkyl substances (PFASs) are a 
group of human-made fluorine-containing 
compounds with unique properties that make 
materials resistant to stains, oil, and water 
(Buck et al. 2011). PFASs have been used 
widely in commercial products since the 
1950s, and they are persistent in the environ-
ment and in living organisms throughout 
the globe (Houde et al. 2006). Human 
exposure routes include contamination of 
food from packaging, bioaccumulation in 
the food chain, and household dust (D’eon 
and Mabury 2011). Perfluorooctane sulfonate 
(PFOS) and perfluorooctanoic acid (PFOA) 
are the two most frequently used PFASs; 
they have estimated biological half-lives in 
humans between 4 and 5 years (Olsen et al. 
2007). PFOS and PFOA concentrations in 
humans were reported to be decreasing in 
some countries following a drop in produc-
tion since 2000 (Kato et al. 2011), but 
exposure to other short-chain compounds 
such as perfluorobutane sulfonate (PFBS) and 
perfluorohexane sulfonate (PFHxS) and long-
chain perfluorononanoic acid (PFNA) and 
perfluorodecanoic acid (PFDA) are reported 
to be increasing (Glynn et al. 2012).
PFASs can cross the placental barrier and 
expose the fetus during the most vulnerable 
period of development (Fei et al. 2007). 
Experimental data suggest that PFASs may be 
developmental neurotoxicants that can affect 
neuronal cell development (Slotkin et al. 
2008), alter cognitive function, and reduce 
habituation and learning ability in mice 
(Johansson et al. 2008, 2009; Viberg et al. 
2013). PFASs also have endocrine-disruptive 
properties (Kjeldsen and Bonefeld-Jørgensen 
2013) and might interfere with thyroid 
hormone function (Lau et al. 2003; Lin et al. 
2013; Long et al. 2013; Wang et al. 2014), 
which is essential in regulating fetal brain 
development (Porterfield 2000).
Attention deficit/hyperactivity disorder 
(ADHD) is considered one of the most 
common neurobehavioral disorders world-
wide, and is characterized by inattention, 
hyperactivity, increased impulsivity, and 
 motivational/emotional dysregulation 
(Polanczyk et al. 2007). Autism is a neurode-
velopmental disorder characterized by impair-
ments in communication and reciprocal social 
interaction, coupled with repetitive behavior 
(Pickett and London 2005). The incidence 
of ADHD and autism has increased over the 
past decades, and it has been suggested that 
the rise is not attributable solely to changes 
in diagnostic practices or parental awareness 
(Faraone et al. 2003; Hertz-Picciotto and 
Delwiche 2009; Møller et al. 2007). The etiol-
ogies are not well understood, but both envi-
ronmental and genetic factors are thought to 
contribute to ADHD and autism (Lyall et al. 
2014; Millichap 2008). ADHD and autism 
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Background: Perfluoroalkyl substances (PFASs) are persistent pollutants found to be endocrine 
disruptive and neurotoxic in animals. Positive correlations between PFASs and neurobehavioral 
problems in children were reported in cross-sectional data, but findings from prospective studies 
are limited.
oBjectives: We investigated whether prenatal exposure to PFASs is associated with attention 
deficit/hyperactivity disorder (ADHD) or childhood autism in children.
Methods: Among 83,389 mother–child pairs enrolled in the Danish National Birth Cohort 
during 1996–2002, we identified 890 ADHD cases and 301 childhood autism cases from the 
Danish National Hospital Registry and the Danish Psychiatric Central Registry. From this cohort, 
we randomly selected 220 cases each of ADHD and autism, and we also randomly selected 550 
controls frequency matched by child’s sex. Sixteen PFASs were measured in maternal plasma 
collected in early or mid-pregnancy. We calculated risk ratios (RRs) using generalized linear models, 
taking into account sampling weights.
results: Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) were detected in 
all samples; four other PFASs were quantified in ≥ 90% of the samples. We did not find consistent 
evidence of associations between mother’s PFAS plasma levels and ADHD [per natural log nano-
grams per milliliter increase: PFOS RR = 0.87 (95% CI: 0.74, 1.02); PFOA RR = 0.98 (95% CI: 
0.82, 1.16)] or autism [per natural log nanograms per milliliter increase: PFOS RR = 0.92 (95% CI: 
0.69, 1.22); PFOA RR = 0.98 (95% CI: 0.73, 1.31)]. We found positive as well as negative asso-
ciations between higher PFAS quartiles and ADHD in models that simultaneously adjusted for all 
PFASs, but these estimates were imprecise.
conclusions: In this study we found no consistent evidence to suggest that prenatal PFAS 
exposure increases the risk of ADHD or childhood autism in children.
citation: Liew Z, Ritz B, von Ehrenstein OS, Bech BH, Nohr EA, Fei CY, Bossi R, 
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disproportionately affect boys (Arnold 1996), 
and studies suggest that prenatal exposure to 
endocrine-disrupting chemicals may be asso-
ciated with the occurrence of both diseases 
(de Cock et al. 2012).
A limited number of epidemiologic studies 
have evaluated the potential neuro behavioral or 
neurocognitive impact of PFASs and findings 
were inconclusive. Several cross-sectional 
studies have reported positive associations 
between serum levels of some PFASs with 
impulsivity (Gump et al. 2011) and ADHD 
in children (Hoffman et al. 2010; Stein and 
Savitz 2011). Reverse causality, however, is a 
concern for studies that measure PFAS levels 
in children already diagnosed with ADHD at 
time of blood draw. Little evidence of asso-
ciations was found for prenatal exposures to 
PFOS or PFOA and behavioral problems in 
7-year-old children assessed with the Strengths 
and Difficulties Questionnaires in the prospec-
tive Danish birth cohort (Fei and Olsen 2011). 
A study conducted in a community with high 
long-term exposure to PFOA in contaminated 
drinking water reported that in utero PFOA 
levels were associated with higher Full-Scale 
IQ and decreased ADHD characteristics 
among children 6–12 years of age (Stein et al. 
2013). However, prenatal PFOA exposures 
were estimated based on exposure modeling. 
A recent study examined the associations 
between several endocrine-disrupting chemi-
cals, including PFASs, and autistic behaviors 
in children but no conclusive evidence was 
found, perhaps due to small sample size 
(175 mother–child pairs) and low statistical 
power (Braun et al. 2014).
We conducted a nested case–control 
study within the framework of the Danish 
National Birth Cohort (DNBC) to examine 
whether prenatal exposure to PFASs is associ-
ated with ADHD or autism in children.
Methods
The DNBC is a nationwide cohort study of 
pregnancies and health-related outcomes in 
the children; details have been described else-
where (Olsen et al. 2001). Briefly, pregnant 
women were recruited through their general 
practitioners during early gestation (weeks 
6–12) from 1996 to 2002. About 50% of all 
general practitioners in Denmark participated 
in the study, and 60% of the women invited 
agreed to participate. Women were ineligible 
if they did not speak sufficient Danish for 
interviews or intended not to carry their 
pregnancy to term. Information was collected 
during four computer-assisted telephone 
interviews (twice during pregnancy and twice 
postpartum). Two prenatal maternal blood 
samples were collected and stored, one each 
in the first and second trimester. English 
versions of questionnaires are available online 
(Statens Serum Institut 2013).
Written informed consent was obtained 
from all participants at recruitment. Study 
procedures have been approved by the Danish 
Data Protection Agency and the Institutional 
Review Board at University of California, 
Los Angeles.
Source population. The source population 
for this study consisted of live-born single-
tons along with mothers who participated 
in the first telephone interview, conducted 
approximately during the 12th gestational 
week, and had provided a blood sample at 
least once either during the first or second 
pregnancy trimesters. This resulted in 83,389 
mother–child pairs, with 42,737 boys and 
40,652 girls; we excluded from the original 
DNBC those with an unsuccessful pregnancy 
(n = 6,207), non-singleton births (n = 2,080), 
births with unknown birth outcomes (n = 25) 
or missing dates of birth (n = 99), mothers 
who emigrated (n = 51) or died (n = 3), and 
women who did not participate in the first 
telephone interview (n = 4,578) or did not 
provide a prenatal blood sample (n = 4,609).
Selection of cases and controls. We iden-
tified children who were diagnosed with 
ADHD and autism, respectively, by linking 
DNBC records to the Danish National 
Hospital Registry (Andersen et al. 1999) 
that contains the nationwide data for all 
admissions for somatic illnesses, and also 
to the Danish Psychiatric Central Registry 
(Munk-Jørgensen et al. 1993), which covers 
admissions to all psychiatric hospitals in 
Denmark. The record linkage relied on the 
unique civil registration numbers given to 
all Danish citizens at birth. All diagnoses are 
based on the International Classification of 
Diseases, 10th Revision (ICD-10 codes F90.0 
for ADHD and F84.0 for childhood autism) 
and included inpatient and outpatient records. 
A total of 890 ADHD cases and 301 autism 
cases were identified in the cohort during an 
average of 10.7 years of follow-up (record 
linkage was conducted on 1 August 2011). 
Because of the high costs of measuring PFASs, 
we randomly selected 220 cases of ADHD 
and autism each for inclusion in this study.
We used a case-cohort sampling strategy 
and randomly selected 550 children (440 
males and 110 females) as controls from 
the source population, frequency matched 
to cases by sex. The flow chart of subject 
selection and sampling fractions of cases and 
controls is shown in Figure 1.
PFAS measurements. Details about 
analytic methods for PFASs have been 
described previously (Liew et al. 2014). 
Briefly, the collected maternal blood samples 
were sent by mail to Statens Serum Institut 
in Copenhagen, and separated and stored 
in freezers at –20°C or –80°C or in liquid 
nitrogen. We used 0.1 mL stored maternal 
plasma, and the samples were analyzed at 
the Department of Environmental Science 
at Aarhus University. Most of the samples 
Figure 1. Flow chart of study population selection in the Danish National Birth Cohort. Sampling fraction of 
ADHD cases is 0.2472. Sampling fraction of autism cases is 0.7309. Sampling fractions of control group are 
0.0103 for male and 0.0027 for female.
Excluded if mothers did not participate in
the first telephone interview or did not
provide a blood sample (n = 9,187)    
Ineligible (n = 8,465):
Unsuccessful pregnancies include miscarriage, 
stillbirth, induced abortion, hydatidiform mole, 
ectopic pregnancy (n = 6,207)
Non-singleton births (n = 2,080)
Mother emigrated (n = 51) or died (n = 3)
Unknown birth outcome (n = 25)
Missing dates of birth (n = 99)  
Pregnancies enrolled in DNBC and assessed for
eligibility (n = 101,041)
Eligible (n = 92,576)
Source population (n = 83,389)
42,737 boys, 40,652 girls
890 with ADHD (ICD-10 F90.0)
301 with autism (ICD-10 F84.0)
ADHD case group
(n = 220) 
Autism case group 
(n = 220) 
Control group
(n = 550; 440 boys, 110 girls) 
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(87%) for both cases and controls were 
collected during the first trimester; if the first 
sample was not available, we used the second 
sample collected in the second trimester 
instead. Solid-phase extraction technique 
was used for extraction and purification, and 
PFAS concentrations were measured by liquid 
chromatography–tandem mass spectrometry. 
Measurements were performed in a random 
sequence for cases and controls by laboratory 
personnel blinded to diagnoses and any other 
participant information. Seventeen maternal 
samples (5 ADHD, 7 autism, 5 controls) 
were either not available from the biobank 
or failed the PFAS extraction and purifica-
tion process, and hence were excluded. For 
21 samples included in our current study, 
PFOA and PFOS values previously had been 
analyzed at the 3M Toxicology Laboratory 
for an earlier study in the DNBC (Fei et al. 
2007). For quality control we compared the 
PFOA and PFOS value measured from the 
two laboratories in these samples and found 
high correlations (Pearson r = 0.94 for PFOS 
and r = 0.95 for PFOA).
Of the 16 different PFASs detected 
in maternal plasma, we focused on the six 
PFASs for which at least 90% of all samples 
were above the lower limit of quantitation 
(LLOQ): PFOS, 100%; PFOA, 100%; 
PFHxS, 98%; PFHpS (perfluoroheptane 
sulfonate), 96%; PFNA, 92%; and PFDA, 
90%. The LLOQ for the six PFASs are as 
follows: PFOS, 0.28 ng/mL; PFOA, 0.20 
ng/mL; PFHxS, 0.08 ng/mL; PFHpS, 0.11 
ng/mL; PFNA, 0.27 ng/mL; and PFDA, 0.09 
ng/mL. The full panel for the LLOQ and 
distribution of all PFASs was reported previ-
ously (Liew et al. 2014).
Statistical analysis. We used general-
ized linear models and accounted for the 
sampling fractions of cases and controls to 
estimate risk ratios (RR) and 95% confidence 
intervals (CIs) for prenatal PFAS exposures 
and ADHD or autism. We also performed 
unconditional logistic regression to estimate 
odds ratios (ORs) without applying the 
sampling weights. PFAS concentrations were 
first analyzed as continuous variables (per 
natural-log unit increase). The PFAS values 
were natural-log transformed to reduce the 
influence of outliers, to improve the model 
fit, and to make interpretation simpler and 
more consistent across different PFASs that 
vary in their ranges of concentration. We 
also categorized PFAS values into quartiles 
according to the distribution among controls, 
using the lowest quartile as the reference 
group. Moreover, we fitted generalized 
additive models with a smoothing function 
of natural-log PFAS values to examine poten-
tial nonlinear relations. Five knots were set 
as the upper limit of number of degrees of 
freedom, and we compared model fit and 
visually inspected plots of the smoothed data. 
We did not find evidence for nonlinearity 
between natural-log PFAS values and ADHD 
or autism (data not shown).
Potential confounders were chosen 
a priori considering variables that may 
influence PFAS exposures and previously 
suggested risk factors of ADHD or autism. 
We included maternal age at delivery (≤ 24, 
25–29, 30–34, ≥ 35 years), parity (1, > 1), 
socioeconomic status (low/medium or high), 
maternal smoking (never, ≤ 9 cigarette/day, 
> 9 cigarettes/day) and alcohol drinking (yes, 
no) during pregnancy, mother’s self-reported 
psychiatric illnesses (yes, no), gestational 
week of blood draw (4–8, > 8 week), child’s 
birth year (1998–2000, 2001–2003), and 
the matching factor child’s sex in the final 
model. Socioeconomic status was deter-
mined based on self-reported maternal and 
paternal education and occupation using three 
categories (high, medium, and low): Higher 
education (4 years beyond high school) or 
work in management were classified as high; 
skilled workers and middle-range educa-
tion as medium; and unskilled workers and 
unemployed as low (Bech et al. 2005). To 
determine maternal psychiatric illnesses, we 
asked women to report whether they had 
ever seen a doctor or psychologist because 
of depression, anxiety, childhood psychi-
atric disorder, family problems/life crisis, or 
other mental health problems. Additionally, 
other potential confounders such as father’s 
age at child’s birth, mother’s prepregnancy 
body mass index, whether the pregnancy was 
planned, and season of conception were evalu-
ated but not included in final models because 
they changed effect estimates of interest 
 minimally (< 1%).
To account for PFAS values below the 
LLOQ when PFASs were analyzed as 
continu ous variables, we used multiple impu-
tation (Lubin et al. 2004) with the procedure 
PROC MI in SAS (SAS Institute Inc.) with 
all six PFASs and all covariates included in the 
model. Ten simulated complete data sets were 
generated via imputation, and we employed 
standard analytical procedures to combine the 
results (Yuan 2001).
A Pearson correlat ion matrix for 
the considered PFASs is presented in 
Supplemental Material, Table S1. We 
constructed a “multiple PFAS” model where 
we simultaneously included all PFASs in one 
model to examine whether any single PFAS 
may be of particular importance. We also 
evaluated potential effect measure modification 
by child’s sex; we compared the sex-stratified 
estimates and examined the p-value for the 
PFAS–sex interaction term. For ADHD we 
also conducted analyses in which we excluded 
children born after 2000 because the duration 
of follow-up may not have been long enough 
to identify children with this diagnosis. For 
these stratified analyses we used logistic regres-
sion without applying sampling weights 
because the weighted analyses may underesti-
mate uncertainty in our data when the number 
of actual measured samples is small. Finally, in 
sensitivity analyses we excluded PFAS values 
that were greater than three times the 75th 
percentile (n = 2 PFOA, n = 7 PFHxS, n = 1 
PFNA, n = 2 PFHpS, n = 1 PFDA) to ensure 
that individuals with extreme exposure values 
did not disproportionately influence our 
results. Analyses were performed using SAS 
version 9.2. 
Results
Table 1 presents the demographic charac-
teristics of cases and controls. Table 2 shows 
the median and interquartile range distribu-
tion of maternal PFAS concentrations during 
 pregnancy in cases and controls.
We generally found no association 
between ADHD or autism in children and 
PFAS levels in maternal plasma (modeled 
as natural-log units) (Table 3). We did not 
detect apparent effect modification by 
child’s sex (all PFASs and sex interaction 
p-values ≥ 0.25), but because both diagnoses 
were more prevalent in boys, estimates for 
girls were less precise (see Supplemental 
Material, Table S2).
When we categorized PFAS values, 
mothers in the highest quartile of PFOS, 
PFHxS, PFHpS, and PFDA were less likely 
to have a child diagnosed with ADHD than 
mothers in the lowest quartile, after adjust-
ment for potential confounders (Table 4). 
When all PFASs were simultaneously entered 
into the model, PFOA and PFNA levels 
were positively associated with ADHD, 
whereas negative associations with the other 
compounds persisted, with most showing 
monotonic trends. There was some evidence 
of a positive association between PFHxS 
and autism, though RRs for the highest 
quartile were closer to the null than RRs 
for the second and third quartiles. Similar 
patterns were found with lower precision of 
the estimates when we used logistic regres-
sion without applying sampling weights (see 
Supplemental Material, Table S3).
Results were similar to those from the 
primary models when we performed additional 
sensitivity analyses restricting the analyses to 
children born before 2001 (see Supplemental 
Material, Table S4), and excluding extreme 
PFAS values (results not shown).
Discussion
Overall, our results do not suggest that 
prenatal exposure to PFASs increases the 
risk of ADHD or childhood autism in 
children. We observed some inverse asso-
ciations between several PFASs and ADHD 
Liew et al.
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after controlling for potential confounders. 
In the “multiple PFAS” model, we found 
some positive as well as negative associa-
tions between PFASs and ADHD but these 
might be subject to multicollinearity or 
sparse data bias. Results were mostly close to 
null for autism in both single and multiple 
PFAS models.
Toxicology studies have raised concerns 
that PFASs are neurotoxic and hormone 
disruptive and can impair fetal brain develop-
ment (Johansson et al. 2008; Lau et al. 2003; 
Long et al. 2013). However, some neuro-
toxic effects in rats were observed at doses 
several orders of magnitude higher than the 
PFAS levels found in the U.S. and Danish 
general populations (Butenhoff et al. 2009; 
Fei et al. 2007). Several epidemiologic studies 
have investigated associations between PFASs 
and hyperactivity or behavioral problems in 
children, but the findings have been incon-
clusive (Braun et al. 2014; Fei and Olsen 
2011; Hoffman et al. 2010; Stein and Savitz 
2011; Stein et al. 2013). A previous study 
based on a subset of children from the Danish 
National Birth Cohort found some inverse 
associations between prenatal PFOA, but not 
PFOS, and behavioral problems in 7-year-old 
children measured by (parent-reported) items 
in the Strength and Difficulty Questionnaire 
(Fei and Olsen 2011). Another study also 
suggested a lower prevalence of ADHD char-
acteristics in children associated with higher 
estimated in utero PFOA exposures based on 
the Clinical Confidence Index (Stein et al. 
2013). There is, however, no biologic expla-
nation for PFASs protecting the developing 
brain from ADHD, and potential biases such 
as uncontrolled confounding or selection bias 
might have driven these unexpected findings. 
No apparent associations were found between 
PFASs and autism in current and a previous 
small study (Braun et al. 2014).
Because several PFASs are moderately to 
highly correlated, it is difficult to disentangle 
mixture effects from compound-specific 
effects. A recent in vitro assay reported an 
additive or more than additive antagonistic 
effect for a mixture of compounds (PFHxS, 
PFOS, PFOA, PFNA, and PFDA) on 
androgen receptor function (Kjeldsen and 
Bonefeld-Jørgensen 2013). Unfortunately, 
our sample is too small to allow for inter-
action analyses between different PFASs. 
Further experimental studies are needed to 
determine mechanisms of action for PFAS 
mixtures on biologic targets that could better 
inform our population-based studies in terms 
of the most biologically relevant exposure 
model to be employed.
It has previously been shown that prenatal 
exposure to PFASs can increase the incidence 
of fetal resorption and neonatal deaths in 
animal models (Abbott et al. 2007; Lau et al. 
2007; Luebker et al. 2005). PFASs may inter-
fere with sex and thyroid hormone homeo-
stasis (Kjeldsen and Bonefeld-Jørgensen 
2013; Lin et al. 2013; Wang et al. 2014), 
and it has been suggested that higher PFAS 
levels are associated with reduced fecundity 
in women (Buck Louis et al. 2013; Fei et al. 
2009) and with an increased risk for miscar-
riage (Darrow et al. 2014). It is therefore 
possible that PFAS exposure at a level that 
reduces fetal or neonatal survival, especially 
in high-risk fetuses and infants susceptible to 
neurological disorders such as ADHD and 
autism, could appear to have null or even 
protective effects on adverse neurobehavioral 
outcomes in children based on observational 
studies, because only live-born children can 
be followed up and examined.
There are several strengths in our study. 
First, the PFAS measures were obtained 
from maternal plasma samples collected in 
pregnancy before the assessment of the 
outcomes in the children. Previous studies 
have shown that PFASs are stable in human 
serum, and measurements obtained from 
serum or plasma samples gave comparable 
Table 1. Characteristics of study participants [n (%)].
Characteristic
ADHD 
(n = 220)
Childhood autism 
(n = 220)
Controls 
(n = 550)
Child’s sex
Male 179 (81.4) 187 (85.0) 440 (80.0)
Female 41 (18.6) 33 (15.0) 110 (20.0)
Mother’s age at delivery (years)
≤ 24 37 (16.8) 28 (12.7) 42 (7.6)
25–29 83 (37.7) 81 (36.8) 235 (42.7)
30–34 72 (32.7) 75 (34.1) 201 (36.5)
≥ 35 28 (12.7) 36 (16.4) 72 (13.1)
Socioeconomic status
Low/medium 112 (50.9) 74 (33.6) 209 (38.0)
High 106 (48.2) 144 (65.5) 339 (61.6)
Parity
1 107 (48.6) 119 (54.1) 247 (44.9)
> 1 100 (45.5) 96 (43.6) 288 (52.4)
Maternal drinking during pregnancy
No 79 (35.9) 79 (35.9) 161 (29.3)
Yes 141 (64.1) 141 (64.1) 389 (70.7)
Maternal smoking during pregnancy
Never 139 (63.2) 142 (64.5) 409 (74.4)
≤ 9 cigarettes/day 32 (14.5) 33 (15.0) 64 (11.6)
> 9 cigarettes/day 49 (22.3) 45 (20.5) 77 (14.0)
Mother’s self-reported psychiatric illnesses
No 167 (75.9) 173 (78.6) 469 (85.3)
Yes 53 (24.1) 47 (21.4) 81 (14.7)
Child’s birth year
1998–2000 133 (60.5) 114 (51.8) 322 (58.5)
2001–2003 87 (39.5) 106 (48.2) 228 (41.5)
Gestational weeks at blood draw 
4–8 weeks 87 (39.5) 88 (40.0) 216 (39.3)
> 8 weeks 119 (54.1) 115 (52.3) 305 (55.5)
The missing values for socioeconomic status, parity, and gestational weeks at blood draw are about 1%, 4%, and 7%, 
respectively.
Table 2. Distribution of maternal plasma PFAS concentrations in cases and controls.
Perfluoroalkyl substance Abbreviation
Carbon chain 
lengtha
Percent quantifiable in 
all samples
PFAS concentration (ng/mL) [median (25th, 75th percentile)]b
ADHD (n = 215) Childhood autism (n = 213) Controls (n = 545)
Perfluorooctane sulfonate PFOS 8 100 26.80 (19.20, 35.00) 25.40 (18.73, 32.40) 27.40 (20.40, 35.60)
Perfluorooctanoic acid PFOA 8 100 4.06 (3.08, 5.50) 3.88 (3.08, 5.28) 4.00 (3.01, 5.42)
Perfluorohexane sulfonate PFHxS 6 98 0.84 (0.61, 1.15) 0.92 (0.70, 1.17) 0.92 (0.68, 1.23)
Perfluoroheptane sulfonate PFHpS 7 96 0.30 (0.20, 0.40) 0.28 (0.19, 0.38) 0.30 (0.21, 0.41)
Perfluorononanoic acid PFNA 9 92 0.42 (0.34, 0.52) 0.41 (0.33, 0.51) 0.43 (0.35, 0.56)
Perfluorodecanoic acid PFDA 10 90 0.15 (0.11, 0.20) 0.15 (0.11, 0.20) 0.17 (0.12, 0.23)
aThe number of carbons in the fully fluorinated alkyl chain. bConcentrations for 17 samples (5 ADHD, 7 autism, and 5 controls) were missing because the samples were either not 
available from the biobank or failed the extraction process.
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results (Ehresman et al. 2007). High corre-
lations between maternal and cord blood 
PFAS measures were also reported, and these 
suggested that PFASs measured in maternal 
plasma can be used as a reasonable surrogate 
for fetal exposure levels throughout gesta-
tions (Fei et al. 2007). Furthermore, the 
maternal PFAS levels in our study are similar 
to those previously measured during the same 
time period in the U.S. general population 
(Calafat et al. 2007). Study participants 
were selected from a well-defined nation-
wide pregnancy cohort with an average of 
10.7 years of follow-up, sufficiently long to 
assess the outcomes of interest. The outcome 
measures were clinical diagnoses using stan-
dardized diagnostic criteria from both the 
general and psychiatric hospital registries in 
Denmark, a country with high-quality health 
care and universal coverage for its popula-
tion. Diagnoses of childhood autism recorded 
in the psychiatric registry have previously 
been shown to have high validity: A study 
extracted and reviewed the medical records of 
499 childhood autism cases from the registry 
and confirmed the diagnoses for 94% of the 
cases (Lauritsen et al. 2010). Follow-up was 
conducted through record linkage that did 
not require subjects’ responses, thus mini-
mizing chances for selection bias due to 
subject’s nonresponse.
Our study also has some limitations. 
Both ADHD and autism are about four 
times more prevalent in boys, and because of 
cost limitations we were required to sample 
no more than 220 cases for each diagnostic 
group, resulting in few female cases (n = 41 
with ADHD; n = 33 with autism). Thus, 
our subgroup analyses by sex were relatively 
imprecise for girls, resulting in effect estimates 
with wide CIs. For autism, the cases were 
limited to children diagnosed with child-
hood autism. Although this is the most severe 
disorder of the autism spectrum, it constitutes 
only a part of autistic spectrum disorders; 
specifically children with Asperger’s syndrome 
and other pervasive development disorders 
were not studied. Moreover, we have no 
data for other endocrine-disrupting chemi-
cals, preventing us from evaluating possible 
correlations or interactions of PFASs with 
other ubiquitous environmental chemicals 
with these properties such as polychlori-
nated biphenyls (PCBs), organophosphates, 
bisphenol A, and phthalates (de Cock et al. 
Table 3. Risks ratiosa for ADHD and childhood autism in children according to maternal plasma concen-
trations of PFASb in pregnancy.
Prenatal exposure
ADHDc Childhood autismc
Adjusted RRd  
(95% CI)
Adjusted RRe  
(95% CI)
Adjusted RRd  
(95% CI)
Adjusted RRe  
(95% CI)
PFOS 0.87 (0.74, 1.02) 1.04 (0.70, 1.56) 0.92 (0.69, 1.22) 1.21 (0.69, 2.13)
PFOA 0.98 (0.82, 1.16) 1.21 (0.84, 1.74) 0.98 (0.73, 1.31) 1.15 (0.68, 1.93)
PFHxS 0.97 (0.88, 1.08) 1.05 (0.91, 1.20) 1.10 (0.92, 1.33) 1.26 (1.00, 1.58)
PFNA 0.80 (0.62, 1.03) 0.99 (0.58, 1.70) 0.80 (0.58, 1.11) 0.84 (0.48, 1.49)
PFHpS 0.91 (0.79, 1.05) 0.93 (0.64, 1.36) 0.91 (0.74, 1.12) 0.82 (0.56, 1.22)
PFDA 0.76 (0.64, 0.91) 0.80 (0.58, 1.11) 0.79 (0.63, 1.01) 0.82 (0.53, 1.28)
aInverse probability weights derived from sampling fractions of cases and controls were applied in analyses. bPer 
1 natural-log unit (ng/mL) increase. cWe used 215 ADHD cases, 213 autism cases, and 545 controls in analyses. 
dAdjusted for maternal age at delivery, socioeconomic status, parity, smoking and drinking during pregnancy, psychi-
atric illnesses, gestational week of blood drawn, and child’s sex and birth year. eAdditionally adjusted including all 
PFASs in the model. 
Table 4. Risks ratiosa for ADHD and childhood autism in children according to maternal plasma concentrations of PFAS (in quartiles) in pregnancy.
Prenatal exposureb
ADHD Childhood autism
Crude RR
Adjusted RRc  
(95% CI) 
Adjusted RRd  
(95% CI) Crude RR
Adjusted RRc  
(95% CI) 
Adjusted RRd  
(95% CI)
PFOS (ng/mL)
3.85–20.40 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
20.41–27.40 0.83 0.95 (0.79, 1.15) 0.93 (0.75, 1.15) 0.72 0.91 (0.66, 1.25) 1.05 (0.73, 1.50)
27.41–35.60 0.90 0.93 (0.76, 1.13) 0.86 (0.65, 1.12) 0.80 1.01 (0.73, 1.40) 1.20 (0.77, 1.89)
≥ 35.61 0.78 0.79 (0.64, 0.98) 0.65 (0.47, 0.91) 0.60 0.86 (0.59, 1.25) 1.16 (0.65, 2.09)
PFOA (ng/mL)
0.57–3.01 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
3.02–4.00 1.00 1.02 (0.84, 1.23) 1.24 (0.99, 1.55) 1.05 1.13 (0.82, 1.56) 1.11 (0.76, 1.60)
4.01–5.42 1.13 1.09 (0.90, 1.33) 1.46 (1.14, 1.88) 1.03 1.05 (0.74, 1.47) 0.97 (0.63, 1.48)
≥ 5.43 1.07 1.14 (0.92, 1.40) 2.02 (1.49, 2.75) 0.78 0.95 (0.65, 1.38) 0.93 (0.54, 1.59)
PFHxS (ng/mL)
< LLOQ–0.68 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
0.69–0.92 0.97 1.05 (0.88, 1.26) 0.94 (0.76, 1.15) 1.26 1.33 (0.95, 1.87) 1.55 (1.06, 2.28)
0.93–1.23 0.90 0.94 (0.78, 1.14) 0.82 (0.65, 1.02) 1.38 1.50 (1.08, 2.10) 1.86 (1.25, 2.76)
≥ 1.24 0.64 0.67 (0.54, 0.83) 0.56 (0.43, 0.73) 0.94 1.07 (0.73, 1.56) 1.33 (0.84, 2.11)
PFNA (ng/mL)
< LLOQ–0.35 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
0.36–0.43 1.07 1.08 (0.90, 1.30) 1.29 (1.05, 1.59) 1.06 1.06 (0.78, 1.44) 0.94 (0.66, 1.34)
0.44–0.56 1.28 1.12 (0.93, 1.33) 1.48 (1.18, 1.86) 1.03 0.81 (0.59, 1.11) 0.73 (0.49, 1.08)
≥ 0.57 0.75 0.85 (0.69, 1.04) 1.58 (1.17, 2.13) 0.70 0.80 (0.56, 1.12) 0.98 (0.59, 1.63)
PFHpS (ng/mL)
< LLOQ–0.21 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
0.21–0.30 0.74 0.70 (0.58, 0.84) 0.67 (0.54, 0.83) 0.83 0.82 (0.60, 1.12) 0.70 (0.49, 1.01)
0.31–0.41 0.91 0.87 (0.72, 1.05) 0.86 (0.65, 1.13) 0.82 0.92 (0.66, 1.29) 0.83 (0.53, 1.31)
≥ 0.42 0.75 0.71 (0.58, 0.87) 0.81 (0.57, 1.15) 0.66 0.82 (0.57, 1.19) 0.80 (0.44, 1.48)
PFDA (ng/mL)
< LLOQ–0.12 1.00 1.00 (reference) 1.00 (reference) 1.00 1.00 (reference) 1.00 (reference)
0.13–0.17 0.91 0.82 (0.69, 0.97) 0.80 (0.66, 0.96) 1.04 0.93 (0.69, 1.25) 0.99 (0.72, 1.37)
0.18–0.23 0.83 0.87 (0.72, 1.05) 0.91 (0.73, 1.14) 0.98 1.07 (0.77, 1.47) 1.34 (0.92, 1.95)
≥ 0.24 0.51 0.53 (0.43, 0.66) 0.53 (0.40, 0.72) 0.50 0.52 (0.35, 0.77) 0.73 (0.43, 1.24)
aInverse probability weights derived from sampling fractions of cases and controls were applied in analyses. bPFAS values below the LLOQ were grouped in the lowest quartile. 
cAdjusted for maternal age at delivery, socioeconomic status, parity, smoking and drinking during pregnancy, psychiatric illnesses, gestational week of blood drawn, and child’s sex 
and birth year. dAdditionally adjusted including all PFASs in the model.
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2012; Polanska et al. 2012). Further, our 
blood samples had to be transported to the 
laboratory by ordinary mail before being 
processed, which may have induced some 
random measurement errors.
In summary, we found no consistent 
evidence that prenatal PFAS exposures were 
associated with ADHD or childhood autism 
in children in the Danish National Birth 
Cohort. Both weak negative associations as 
well as some positive associations between 
PFASs and ADHD that we observed in 
multiple PFAS models should be further 
explored. We recommend that future studies 
analyze a larger sample, consider both prenatal 
exposure and exposure during first year of 
life, assess the potential mixture effects of 
exposures to different co-occurring endocrine 
disruptors, and examine more sensitive indica-
tors such as neuropsychological functioning 
in children.
RefeRence
Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, 
Helfant L, et al. 2007. Perfluorooctanoic acid–induced 
developmental toxicity in the mouse is dependent 
on expression of peroxisome  proliferator–activated 
receptor-alpha. Toxicol Sci 98:571–581.
Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, 
Olsen JH. 1999. The Danish National Hospital 
Register. A valuable source of data for modern 
health sciences. Dan Med Bull 46:263–268.
Arnold LE. 1996. Sex differences in ADHD: conference 
summary. J Abnorm Child Psychol 24:555–569.
Braun JM, Kalkbrenner AE, Just AC, Yolton K, 
Calafat  AM, Sjödin A, et  al. 2014. Gestational 
exposure to endocrine-disrupting chemicals 
and reciprocal social, repetitive, and stereotypic 
behaviors in 4- and 5-year-old children: the HOME 
study. Environ Health Perspect 122:513–520; 
doi:10.1289/ehp.1307261.
Bech BH, Nohr EA, Vaeth M, Henriksen TB, Olsen J. 
2005. Coffee and fetal death: a cohort study with 
prospective data. Am J Epidemiol 162:983–990.
Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, 
de Voogt P, et al. 2011. Perfluoroalkyl and poly-
fluoroalkyl substances in the environment: termi-
nology, classification, and origins. Integr Environ 
Assess Manag 7:513–541.
Buck Louis GM, Sundaram R, Schisterman EF, 
Sweeney AM, Lynch CD, Gore-Langton RE, et al. 
2013. Persistent environmental pollutants and 
couple fecundity: the LIFE study. Environ Health 
Perspect 121:231–236; doi:10.1289/ehp.1205301.
Butenhoff JL, Ehresman DJ, Chang SC, Parker GA, 
Stump  DG. 2009. Gestational and lactational 
exposure to potassium perfluorooctanesulfonate 
(K+PFOS) in rats: developmental neurotoxicity. 
Reprod toxicol 27:319–330.
Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, 
Needham LL. 2007. Serum concentrations of 11 
polyfluoroalkyl compounds in the U.S. popula-
tion: data from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2000. Environ 
Sci Technol 41:2237–2242.
Darrow LA, Howards PP, Winquist A, Steenland K. 
2014. PFOA and PFOS serum levels and miscar-
riage risk. Epidemiology 25:505–512.
de  Cock M, Maas YG, van  de  Bor M. 2012. Does 
perinatal exposure to endocrine disruptors induce 
autism spectrum and attention deficit hyperactivity 
disorders? Review. Acta Paediatr 101:811–818.
D’eon JC, Mabury SA. 2011. Is indirect exposure a 
significant contributor to the burden of perfluo-
rinated acids observed in humans? Environ Sci 
Technol 45:7974–7984.
Ehresman DJ, Froehlich JW, Olsen GW, Chang SC, 
Butenhoff JL. 2007. Comparison of human whole 
blood, plasma, and serum matrices for the determi-
nation of perfluorooctanesulfonate (PFOS), perfluo-
rooctanoate (PFOA), and other fluorochemi cals. 
Environ Res 103:176–184.
Faraone SV, Sergeant J, Gillberg C, Biederman J. 
2003. The worldwide prevalence of ADHD: is it an 
American condition? World Psychiatry 2:104–113.
Fei CY, McLaughlin JK, Lipworth L, Olsen J. 2009. 
Maternal levels of perfluorinated chemicals and 
subfecundity. Hum Reprod 24:1200–1205.
Fei CY, McLaughlin JK, Tarone RE, Olsen J. 2007. 
Perfluorinated chemicals and fetal growth: a study 
within the Danish National Birth Cohort. Environ 
Health Perspect 115:1677–1682; doi:10.1289/
ehp.10506.
Fei CY, Olsen J. 2011. Prenatal exposure to perfluori-
nated chemicals and behavioral or coordination 
problems at age 7 years. Environ Health Perspect 
119:573–578; doi:10.1289/ehp.1002026.
Glynn A, Berger U, Bignert A, Ullah S, Aune M, 
Lignell S, et al. 2012. Perfluorinated alkyl acids in 
blood serum from primiparous women in Sweden: 
serial sampling during pregnancy and nursing, and 
temporal trends 1996–2010. Environ Sci Technol 
46:9071–9079.
Gump  BB, Wu Q, Dumas AK, Kannan K. 2011. 
Perfluorochemical (PFC) exposure in children: 
associations with impaired response inhibition. 
Environ Sci Technol 45:8151–8159.
Hertz-Picciotto I, Delwiche L. 2009. The rise in autism 
and the role of age at diagnosis. Epidemiology 
20:84–90.
Hoffman K, Webster TF, Weisskopf MG, Weinberg J, 
Vieira VM. 2010. Exposure to polyfluoroalkyl chem-
icals and attention deficit/hyperactivity disorder in 
U.S. children 12–15 years of age. Environ Health 
Perspect 118:1762–1767; doi:10.1289/ehp.1001898.
Houde M, Martin JW, Letcher RJ, Solomon KR, 
Muir DC. 2006. Biological monitoring of polyfluo-
roalkyl substances: a review. Environ Sci Technol 
40:3463–3473.
Johansson N, Eriksson P, Viberg H. 2009. Neonatal 
exposure to PFOS and PFOA in mice results in 
changes in proteins which are important for 
neuronal growth and synaptogenesis in the 
 developing brain. Toxicol Sci 108:412–418.
Johansson N, Fredriksson A, Eriksson P. 2008. Neonatal 
exposure to perfluorooctane sulfonate (PFOS) 
and perfluorooctanoic acid (PFOA) causes neuro-
behavioural defects in adult mice. Neurotoxicology 
29:160–169.
Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM. 2011. 
Trends in exposure to polyfluoroalkyl chemicals in 
the U.S. population: 1999–2008. Environ Sci Technol 
45:8037–8045.
Kje ldsen LS,  Bonefeld-Jørgensen EC.  2013 . 
Perfluorinated compounds affect the function of 
sex hormone receptors. Environ Sci Pollut Res Int 
20:8031–8044.
Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, 
Seed J. 2007. Perfluoroalkyl acids: a review of 
monitoring and toxicological findings. Toxicol Sci 
99:366–394.
Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, 
Stanton ME, et al. 2003. Exposure to perfluorooctane 
sulfonate during pregnancy in rat and mouse. II: 
Postnatal evaluation. Toxicol Sci 74:382–392.
Lauritsen MB, Jørgensen M, Madsen KM, Lemcke S, 
Toft S, Grove J, et al. 2010. Validity of childhood 
autism in the Danish Psychiatric Central Register: 
findings from a cohort sample born 1990–1999. 
J Autism Dev Disord 40:139–148.
Liew Z, Ritz B, Bonefeld-Jørgensen EC, Henriksen TB, 
Nohr EA, Bech BH, et al. 2014. Prenatal exposure 
to perfluoroalkyl substances and the risk of 
congenital cerebral palsy in children. Am  J 
Epidemiol 180:574–581.
Lin CY, Wen LL, Lin LY, Wen TW, Lien GW, Hsu SHJ, 
et  al. 2013. The associations between serum 
perfluorinated chemicals and thyroid function in 
adolescents and young adults. J Hazard Mater 
244–245:637–644.
Long M, Ghisari M, Bonefeld-Jørgensen  EC. 2013. 
Effects of perfluoroalkyl acids on the function of 
the thyroid hormone and the aryl hydrocarbon 
receptor. Environ Sci Pollut Res Int 20:8045–8056.
Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, 
Severson RK, et al. 2004. Epidemiologic evaluation 
of measurement data in the presence of detec-
tion limits. Environ Health Perspect 112:1691–1696; 
doi:10.1289/ehp.7199.
Luebker DJ, York RG, Hansen KJ, Moore JA, 
Butenhoff  JL. 2005. Neonatal mortality from 
in utero exposure to perfluorooctanesulfonate 
(PFOS) in Sprague-Dawley rats: dose–response, 
and biochemical and pharamacokinetic param-
eters. Toxicology 215:149–169.
Lyall K, Schmidt RJ, Hertz-Picciotto I. 2014. Maternal 
lifestyle and environmental risk factors for autism 
spectrum disorders. Int J Epidemiol 43:443–464; 
doi:10.1093/ije/dyt282.
Millichap JG. 2008. Etiologic classification of 
attention- deficit/hyperactivity disorder. Pediatrics 
121:e358–e365.
Møller LR, Sørensen MJ, Thomsen PH. 2007. ICD-10 
classification in Danish child and adolescent 
psychiatry—have diagnoses changed after the 
introduction of ICD-10? Nord J Psychiat 61:71–78.
Munk-Jørgensen P, Kastrup M, Mortensen PB. 1993. 
The Danish Psychiatric Register as a tool in epide-
miology. Acta Psychiatr Scand Suppl 370:27–32.
Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, 
Seacat AM, Butenhoff JL, et al. 2007. Half-life of 
serum elimination of perfluorooctanesulfonate, 
perfluoro hexanesulfonate, and perfluorooctanoate 
in retired fluorochemical production workers. 
Environ Health Perspect 115:1298–1305; doi:10.1289/
ehp.10009.
Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, 
Andersen AM, et al. 2001. The Danish National 
Birth Cohort—its background, structure and aim. 
Scand J Public Health 29:300–307.
Pickett J, London E. 2005. The neuropathology of 
autism: a review. J Neuropathol Exp Neurol 
64:925–935.
Polanczyk G, de Lima MS, Horta BL, Biederman J, 
Rohde LA. 2007. The worldwide prevalence of 
ADHD: a systematic review and metaregression 
analysis. Am J Psychiatry 164:942–948.
Polanska K, Jurewicz J, Hanke W. 2012. Exposure to 
environmental and lifestyle factors and attention-
deficit/hyperactivity disorder in children—a review 
of epidemiological studies. Int J Occup Med 
Environ Health 25:330–355.
Porterfield SP. 2000. Thyroidal dysfunction and 
environmental chemicals—potential impact on 
brain development. Environ Health Perspect 
108(suppl 3):433–438.
Slotkin TA, MacKillop EA, Melnick RL, Thayer KA, 
Perfluoroalkyl substances, ADHD, and childhood autism
Environmental Health Perspectives • volume 123 | number 4 | April 2015 373
Seidler  FJ. 2008. Developmental neurotoxicity 
of perfluorinated chemicals modeled in  vitro. 
Environ Health Perspect 116:716–722; doi:10.1289/
ehp.11253.
Statens Serum Institut. 2013. Access to DNBC (Danish 
National Birth Cohort) data. Available: http://
www.ssi.dk/English/RandD/Research%20areas/
Epidemiology/DNBC/For%20researchers.aspx 
[accessed 1 April 2013].
Stein CR, Savitz DA. 2011. Serum perfluorinated 
compound concentration and attention deficit/
hyperactivity disorder in children 5–18 years of age. 
Environ Health Perspect 119:1466–1471; doi:10.1289/
ehp.1003538.
Stein CR, Savitz DA, Bellinger DC. 2013. Perfluoro-
octanoate and neuropsychological outcomes in 
children. Epidemiology 24:590–599.
Viberg H, Lee I, Eriksson P. 2013. Adult dose-dependent 
behavioral and cognitive disturbances after a single 
neonatal PFHxS dose. Toxicology 304:185–191.
Wang Y, Rogan WJ, Chen PC, Lien GW, Chen HY, 
Tseng YC, et al. 2014. Association between maternal 
serum perfluoroalkyl substances during pregnancy 
and maternal and cord thyroid hormones: Taiwan 
Maternal and Infant Cohort Study. Environ Health 
Perspect 122:529–534; doi:10.1289/ehp.1306925. 
Yuan Y. 2001. Multiple Imputation for Missing Data: 
Concepts and New Development. Rockville, 
MD:SAS Institute Inc. Available: https://support.
sas.com/rnd/app/stat/papers/multipleimputation.
pdf [accessed 18 March 2015].
